Talimogene laherparepvec (T-Vec, OncoVEX),31 a HSV-1-derived herpes virus expressing GM-CSF, recently has completed a phase 3 trial on patients with advanced malignant melanoma (NCT00769704, Figure 5a). Here, CSF2 is linked to melanoma.